| Literature DB >> 35621862 |
Adnan Haider1,2, Irfan Azmatullah Khwaja2, Abdul Basit Qureshi3, Imran Khan4, Khalid Abdul Majeed1, Muhammad Shahbaz Yousaf1, Hafsa Zaneb5, Abdul Rehman6, Imtiaz Rabbani1, Sajid Khan Tahir1, Habib Rehman1.
Abstract
BACKGROUND: Intraoperative hypothermia is an integral part of cardiopulmonary bypass (CPB), and a precise degree of hypothermia may improve the early clinical outcomes of cardiac surgery. Presently, there is no agreement on an accurate, advantageous temperature range for routine use in CPB. To address this issue, we conducted a retrospective observational study to compare the effects of different hypothermic temperature ranges on primary (inotropic support, blood loss, and platelet count) and secondary (ventilation support and in-hospital stay) outcomes in patients undergoing elective cardiac surgery.Entities:
Keywords: blood loss; cardiac surgery; in-hospital stay; inotropic support; thrombocytopenia
Year: 2022 PMID: 35621862 PMCID: PMC9145413 DOI: 10.3390/jcdd9050151
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Distribution of surgical procedures in hypothermic groups.
| Surgical Procedure | Type of Hypothermia | Total | |||
|---|---|---|---|---|---|
| Moderate | Intermediate | Mild | |||
| Atrial septal defect | 1 (1.23) | 1 (1.12) | 1 (1.33) | 3 (1.22) | 0.993 |
| Aortic valve replacement | 2 (2.46) | 9 (10.11) | 4 (5.33) | 15 (6.12) | 0.109 |
| Coronary artery bypass grafting (CABG) | 62(76.54) | 60 (67.41) | 56 (74.66) | 178 (72.65) | 0.368 |
| CABG (1 graft) | 12 (19.35) | 08 (13.33) | 11 (19.64) | 31 (17.41) | 0.428 |
| CABG (2 grafts) | 20 (32.25) | 29 (48.33) | 28 (50.00) | 77 (43.25) | 0.164 |
| CABG (3 grafts) | 30 (48.38) | 23 (38.33) | 18 (32.14) | 71 (39.88) | 0.214 |
| CABG + Mitral valve replacement | 0 (0.00) | 2 (2.24) | 0 (0.00) | 2 (0.81) | 0.171 |
| CABG + Aortic valve replacement | 1 (1.23) | 1 (1.12) | 0 (0.00) | 2 (0.81) | 0.639 |
| Double valve replacement | 3 (3.70) | 1 (1.12) | 4 (5.33) | 8 (3.26) | 0.308 |
| Mitral valve replacement | 11 (13.58) | 13 (14.60) | 8 (10.66) | 32 (13.06) | 0.746 |
| Triple valve replacement | 1 (1.23) | 2 (2.24) | 2 (2.66) | 5 (2.04) | 0.807 |
| Total | 81 (33.07) | 89 (36.32) | 75 (30.61) | 245 (100.00) | 0.581 |
Moderate hypothermia (28 °C to 30 °C); intermediate hypothermia (31 °C to 33 °C); mild hypothermia (34 °C to 36 °C). Data are presented as n = number of patients and percentage, with Pearson’s chi-squared test to calculate the p-value.
Baseline characteristics of patients undergoing cardiopulmonary bypass.
| Parameter | Types of Hypothermia; Median (Range) | |||
|---|---|---|---|---|
| Moderate ( | Intermediate ( | Mild ( | ||
| Age (years) | 55 (24–75) | 54 (19–70) | 55 (20–73) | 0.777 |
| Gender; male; | 66 (81.00) | 73 (82.02) | 58 (77.33) | 0.720 |
| History of diabetes mellitus; | 32 (39.50) | 26 (29.21) | 21 (28.00%) | 0.275 |
| History of smoking; | 20 (24.69) | 23 (25.84) | 17 (22.66) | 0.894 |
| Weight (kg) | 71.10 (51.90–126.10) | 71.70 (50.80– 127.40) | 72.40 (50.90–96.50) | 0.216 |
| Height (cm) | 165 (143–190) | 169 (146–195) | 164 (140–193) | 0.599 |
| Body mass index (kg/m2) ‡ | 27.12 ± 4.30 | 26.60 ± 5.00 | 26.06 ± 4.35 | 0.361 |
| Ejection fraction (%) | 55 (30–57) | 52 (32–57) | 57 (30–58) | 0.444 |
| EuroSCORE-II | 1.40 (1.10–3.60) | 1.50 (1.00–4.00) | 1.40 (1.20–3.80) | 0.870 |
| Blood urea (mg/dL) | 32 (16–83) | 30 (11–73) | 29 (17–56) | 0.621 |
| Bilirubin (mg/dL) | 0.70 (0.30–2.60) | 0.60 (0.20–2.00) | 0.80 (0.40–2.40) | 0.040 |
| SGPT (U/L) | 28 (12–181) | 29 (7–121) | 25 (15–156) | 0.559 |
| SGOT (U/L) | 35 (13–297) | 34 (12–159) | 35 (16–151) | 0.412 |
| Leukocyte count (103/μL) | 9.25 (4.90–19.50) | 9.37 (4.20–19.60) | 9.50 (5.20–19.80) | 0.575 |
| Platelets count (103/μL) | 202 (68–662) | 242 (87–661) | 235 (130–591) | 0.182 |
Moderate hypothermia (28 °C to 30 °C); intermediate hypothermia (31 °C to 33 °C); mild hypothermia (34 °C to 36 °C). † Data are presented as n = number of patients and percentage. ‡ Values are expressed as mean ± SD. SGPT = Serum glutamic pyruvic transaminase; SGOT = Serum glutamic oxaloacetic transaminase.
Multivariable regression analysis for primary and secondary endpoints.
| Reference Group * | Incidence Rate Ratios/Odds Ratio (95% CI) | R2 Nagelkerke | ||
|---|---|---|---|---|
| Mild | Intermediate | Moderate | ||
| Primary endpoints: | ||||
| Adrenaline infusion rate | 0.06 (0.05–0.06) mcg/kg/min | 0.96 (0.81–1.14) | 1.29 (1.09–1.52) | 0.066 |
| Dopamine infusion rate | 3.88 (3.70–4.06) mcg/kg/min | 1.09 (1.02–1.16) | 1.00 (0.94–1.07) | 0.05 |
| Total Blood loss | 383.87 (352.09–417.50) mL | 1.75 (1.58–1.95) | 1.73 (1.56–1.93) <0.001 | 1.00 |
| Blood transfusion ** | Reference | 4.50 (1.59–16.17) | 5.82 (2.07–20.84) | 0.046 |
| Platelet count | 270.4 (265.0–275.9) × 103/μL | 0.95 (0.93–0.97) | 0.88 (0.86–0.90) <0.001 | 0.82 |
| Secondary endpoints: | ||||
| Ventilation time | 126.8 (109.8–145.4) minutes | 1.27 (1.06–1.52) | 1.80 (1.51–2.14) | 1.00 |
| In-hospital stay | 7.05 (6.47–7.67) days | 1.12 (1.00–1.26) | 1.13 (1.01–1.27) | 0.108 |
* Baseline values of the endpoints for the reference group, i.e., mild hypothermia, considering a reference IRR = 1.00. ** The values for blood transfusion are presented as odds ratios (95% CI) and R2 Tjur. Moderate hypothermia (28 °C to 30 °C); intermediate hypothermia (31 °C to 33 °C); mild hypothermia (34 °C to 36 °C).
Intraoperative and postoperative characteristics of patients undergoing cardiopulmonary bypass (CPB).
| Parameter | Types of Hypothermia; Median (Range) | |||
|---|---|---|---|---|
| Moderate ( | Intermediate ( | Mild ( | ||
| Intraoperative Phase: | ||||
| CPB time (minutes) | 106 (61–264) | 110 (52–225) | 100 (57–191) | 0.058 |
| ACC (minutes) | 68 (29–148) | 72 (28–169) | 55 (34–171) | 0.009 |
| Blood sugar random (mg/dL) † | 207.30 ± 71.03 | 224.21 ± 65.70 | 218.11 ± 70.03 | 0.274 |
| CeO2 at 30 min (%) | 23 (20–25) | 24 (20–27) | 32 (30–34) | <0.001 |
| CeO2 at rewarming (%) | 35 (26–40) | 32 (28–35) | 34 (28–37) | <0.001 |
| Hemoglobin (g/dL) † | 8.61 ± 1.39 | 8.79 ± 1.78 | 8.90 ± 1.74 | 0.540 |
| Postoperative Phase: | ||||
| Hemoglobin (g/dL) † | 9.80 ± 1.462 | 9.76 ± 1.546 | 9.93 ± 1.467 | 0.761 |
| SGPT (U/L) | 31 (14–617) | 33 (15–256) | 34 (11–359) | 0.728 |
| SGOT (U/L) | 62 (19–310) | 61 (22–327) | 51 (21–384) | 0.047 |
| Leukocyte count (103/μL) | 18.90 (7.80–48.00) | 17.90 (5.90–30.70) | 18.70 (9.30–48.80) | 0.422 |
| ICU stay (days) | 5 (3–10) | 5 (1–9) | 5 (1–10) | 0.636 |
| Mortality; | 1 (1.23) | 1 (1.12) | 0 (0.00) | 0.639 |
Moderate hypothermia (28 °C to 30 °C); intermediate hypothermia (31 °C to 33 °C); mild hypothermia (34 °C to 36 °C); ACC = Aortic cross-clamp time; CeO2 = Cerebral oxygen expenditure; SGPT = Serum glutamic pyruvic transaminase; SGOT = Serum glutamic oxaloacetic transaminase. † Data are presented as n = number of patients and percentage. ‡ Values are expressed as mean ± SD.